PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY
Status:
RECRUITING
Trial end date:
2028-05-30
Target enrollment:
Participant gender:
Summary
To explore the safety and efficacy of Tegafur combined with tislelizumab in patients with esophageal squamous cell carcinoma with residual primary lesion and node-negative after radical resection following neoadjuvant immunotherapy combined with chemotherapy
Phase:
PHASE2
Details
Lead Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University